Whole-body Diffusion-weighted Magnetic Resonance Imaging and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence Following Surgery or Systemic Therapy
Who is this study for? Patients with Melanoma
What treatments are being studied? Follow Up DW MRI
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Patients with locally advanced melanoma are at high risk for recurrence following surgical treatment. More patients with stage IV melanoma remain in complete remission following systemic therapy. No standards have been established for the surveillance of patients at high risk for recurrence. Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis of blood are innovative imaging and laboratory investigations that may be of benefit for early detection of recurrence in this patient population.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Histologically confirmed malignant melanoma;
• AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
• Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
Locations
Other Locations
Belgium
UZ Brussel
RECRUITING
Brussels
UZ Brussel
RECRUITING
Jette
Contact Information
Primary
Bart Neyns, MD Phd
bart.neyns@uzbrussel.be
02 477 60 40
Backup
Yanina JL Jansen, MD
yanina.jansen@uzbrussel.be
02 477 91 23
Time Frame
Start Date: 2014-11
Estimated Completion Date: 2025-11
Participants
Target number of participants: 100
Treatments
Experimental: stage IV melanoma CR>3years
Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
Experimental: Stage III Melanoma
AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
Related Therapeutic Areas
Sponsors
Leads: Universitair Ziekenhuis Brussel